Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?

It has been about a month since the last earnings report for OPKO Health (OPK). Shares have lost about 9.7% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is OPKO Health due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important drivers.

OPKO Health Q2 Earnings & Revenues Beat Estimates

OPKO Health, Inc. reported a second-quarter 2026 loss of 1 cent per share, narrower than the year-ago quarter's loss of 19 cents. The figure beat the Zacks Consensus Estimate of a loss of 8 cents by 87.5%.

Revenues rose 4.3% year over year to $163.6 million, driven by strong growth in the Pharmaceuticals segment. The top line also surpassed the Zacks Consensus Estimate by 24.7%.

The better-than-expected performance reflected higher pharmaceutical revenues, including income related to the amended Nicoya licensing agreement, partially offset by lower Diagnostics revenues following last year's oncology asset divestiture.

Q2 Segment Details

Total pharmaceutical revenues increased 59.8% year over year to $89 million. The upside was primarily driven by higher product sales and a significant increase in revenues from intellectual property transfers and other sources.

Diagnostics service revenues declined 26.3% year over year to $74.5 million. The comparison was affected by the sale of OPK's oncology assets to Labcorp in September 2025, which contributed $24.9 million to revenues in the prior-year quarter.

Excluding the divested oncology business, core diagnostics revenues declined modestly to $68.2 million from $69.3 million a year ago. Revenues from the 4Kscore prostate cancer test fell to $6.3 million from $6.9 million. Management attributed the decline primarily to changes in test mix following the transfer of certain lower-margin esoteric tests to strategic partners.

OPK’s Product Sales Improve

Product revenues increased 5.4% year over year to $42.9 million. Growth was supported by higher sales volumes in the company's Spanish and Mexican operations, along with a favorable foreign exchange impact of $1.8 million. These gains were partially offset by approximately $1.7 million of lower revenues across other international markets.

RAYALDEE revenues increased to $8.1 million from $7.2 million in the prior-year quarter, mainly driven by favorable gross-to-net adjustments. Management stated that international pharmaceutical operations continued to perform well, while RAYALDEE sales remained ahead of internal expectations.

OPK’s Margin Expands as Costs Decline

For the second quarter, gross profit increased to $80 million from $49.4 million a year ago, while gross margin expanded to 48.9% from 31.5%. The improvement reflected lower service costs following the Diagnostics asset sale and a higher contribution from intellectual property and other revenues, including income tied to the amended Nicoya agreement.

Total costs and expenses declined 21.3% year over year to $170.6 million. Cost of service revenues fell 29% year over year to $58.5 million, while selling, general and administrative expenses declined 11.2% to $52.9 million. Research and development expenses increased 9.3% year over year to $33.2 million, reflecting continued investment in early-stage clinical programs.

Consolidated operating loss narrowed to $7 million from $60 million, aided by higher pharmaceutical revenues, lower Diagnostics costs and an $18.1 million Labcorp earnout gain. The Diagnostics segment posted an operating income of $4.8 million against an operating loss of $18.2 million a year ago.

Cash Position

OPKO Health exited the second quarter with cash, cash equivalents, marketable securities and restricted cash of $314.4 million compared with $341.9 million at the first-quarter end.

During the quarter, the company repurchased $13.2 million worth of common stock. As of June 30, 2026, cumulative share repurchases under the existing authorization totaled approximately $105.3 million, with $94.7 million still available for future buybacks.

Cumulative net cash used in operating activities at the end of second-quarter 2026 was $62.8 million compared with $117.9 million a year ago.

OPK’s Q3 & FY26 Guidance

For the third quarter of 2026, OPKO Health expects total revenues in the range of $131-$142 million. The outlook includes service revenues of $73-$78 million, product revenues of $40-$44 million and intellectual property and other revenues of $16-$20 million.

Management raised its full-year 2026 revenue guidance to $560-$585 million from the previous range of $530-$560 million.

The company lowered its full-year cost and expense outlook to $710-$740 million from the earlier projection of $725-$750 million. Expected research and development spending remains unchanged at $125-$135 million.

How Have Estimates Been Moving Since Then?

In the past month, investors have witnessed a upward trend in estimates revision.

The consensus estimate has shifted 21.62% due to these changes.

VGM Scores

Currently, OPKO Health has a average Growth Score of C, however its Momentum Score is doing a bit better with a B. However, the stock was allocated a score of F on the value side, putting it in the bottom 20% quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, OPKO Health has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry Player

OPKO Health is part of the Zacks Medical - Instruments industry. Over the past month, Intuitive Surgical, Inc. (ISRG), a stock from the same industry, has gained 2.8%. The company reported its results for the quarter ended June 2026 more than a month ago.

Intuitive Surgical reported revenues of $2.89 billion in the last reported quarter, representing a year-over-year change of +18.5%. EPS of $2.80 for the same period compares with $2.19 a year ago.

Intuitive Surgical is expected to post earnings of $2.61 per share for the current quarter, representing a year-over-year change of +8.8%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Intuitive Surgical. Also, the stock has a VGM Score of C.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research